December decision for resubmitted Pozen NDA
This article was originally published in Scrip
Executive Summary
Less than three months after the US FDA rejected Pozen's new drug application (NDA) for the preventative cardiovascular drugs PA8140 and PA32540, the agency accepted the company's resubmitted NDA for review and set a year-end decision date for the application.